- Conditions
- Corneal Edema
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs' Endothelial Corneal Dystrophy
- Interventions
- Wearing of contact lens
- Device
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
- Interventions
- TTHX1114(NM141)
- Drug
- Lead sponsor
- Trefoil Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- Amphotericin B
- Drug
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 20 Years to 79 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs' Corneal Endothelial Dystrophy (FCED)
- Interventions
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Edgewood, Kentucky • Boston, Massachusetts
- Conditions
- Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,911 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
- Interventions
- EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
- Biological
- Lead sponsor
- Emmecell
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
- Conditions
- Corneal Endothelial Dystrophy, Corneal Edema
- Interventions
- loteprednol etabonate 0.25% ophthalmic suspension
- Drug
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- DSAEK with graft shaping and smoothing, Standard DSAEK
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fuchs Dystrophy, Corneal Edema
- Interventions
- Corneal transplantation
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Dry Eye Disease, Endothelial Cell
- Interventions
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more
- Conditions
- Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
- Interventions
- Brillouin imaging
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
- Interventions
- Combination Product: AURN001 + Y-27632, Placebo
- Drug · Other
- Lead sponsor
- Aurion Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 12
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Interventions
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
- Conditions
- Fuchs Endothelial Dystrophy, Corneal Edema
- Interventions
- Descemet's stripping endothelial keratoplasty
- Procedure
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Interventions
- TTHX1114(NM141), Vehicle (placebo)
- Drug · Other
- Lead sponsor
- Trefoil Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
- Conditions
- Cornea Preservation Time, Endothelial Keratoplasty, Transplant Success, Endothelial Cell Density
- Interventions
- Cornea tissue transplant
- Biological
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 40
- States / cities
- Beverly Hills, California • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
- Conditions
- Fuchs' Endothelial Dystrophy, Cataract
- Interventions
- Netarsudil 0.02% Ophthalmic Solution
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Corneal Endothelial Cell Loss
- Interventions
- Topcon Specular Microscope SP-1P, Konan Specular Microscope CELLCHEK XL
- Device
- Lead sponsor
- Topcon Medical Systems, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts